Zacks Research Lowers Earnings Estimates for DENTSPLY SIRONA

Key Points

• Zacks Research has lowered its Q3 2025 EPS estimates for DENTSPLY SIRONA from $0.46 to $0.42, with a current full-year earnings consensus of $1.84 per share.
• Several analysts have adjusted their price targets, with Barrington Research reducing it from $21.00 to $18.00, indicating a cautious outlook on the stock.
• DENTSPLY SIRONA recently declared a quarterly dividend of $0.16 per share, representing a yield of 4.5%, with the ex-dividend date set for September 26th.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Zacks Research decreased their Q3 2025 EPS estimates for shares of DENTSPLY SIRONA in a report issued on Thursday, August 28th. Zacks Research analyst Team now anticipates that the medical instruments supplier will earn $0.42 per share for the quarter, down from their previous forecast of $0.46. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.84 per share. Zacks Research also issued estimates for DENTSPLY SIRONA's Q4 2025 earnings at $0.46 EPS, Q1 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.48 EPS and Q4 2026 earnings at $0.56 EPS.

XRAY has been the topic of a number of other reports. Barrington Research lowered their price target on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Stifel Nicolaus decreased their price objective on shares of DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a report on Friday, August 8th. Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a research note on Monday, July 21st. UBS Group decreased their price target on shares of DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $18.64.

DENTSPLY SIRONA Stock Down 0.1%

XRAY stock opened at $14.30 on Monday. The firm's fifty day simple moving average is $15.15 and its 200-day simple moving average is $15.32. DENTSPLY SIRONA has a 12 month low of $12.16 and a 12 month high of $27.48. The company has a market capitalization of $2.85 billion, a P/E ratio of -3.02, a price-to-earnings-growth ratio of 0.89 and a beta of 0.96. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.50 by $0.02. The business had revenue of $936.00 million for the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. The business's revenue for the quarter was down 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cim Investment Management Inc. increased its position in DENTSPLY SIRONA by 99.7% during the second quarter. Cim Investment Management Inc. now owns 48,321 shares of the medical instruments supplier's stock worth $842,000 after purchasing an additional 24,120 shares during the last quarter. Continental Advisors LLC increased its position in shares of DENTSPLY SIRONA by 10.0% during the second quarter. Continental Advisors LLC now owns 226,081 shares of the medical instruments supplier's stock valued at $3,590,000 after acquiring an additional 20,600 shares during the last quarter. State of Wyoming increased its position in shares of DENTSPLY SIRONA by 52.8% during the second quarter. State of Wyoming now owns 19,091 shares of the medical instruments supplier's stock valued at $303,000 after acquiring an additional 6,596 shares during the last quarter. Pitcairn Co. acquired a new stake in shares of DENTSPLY SIRONA during the second quarter valued at about $160,000. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of DENTSPLY SIRONA by 1.7% during the second quarter. CANADA LIFE ASSURANCE Co now owns 205,811 shares of the medical instruments supplier's stock valued at $3,268,000 after acquiring an additional 3,352 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 10th. Investors of record on Friday, September 26th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 4.5%. The ex-dividend date is Friday, September 26th. DENTSPLY SIRONA's dividend payout ratio (DPR) is presently -13.50%.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.